Pyoderma Gangrenosum Clinical Trials

40 clinical trials for Pyoderma Gangrenosum across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum — RECRUITING · PHASE3
• Optical Coherence Tomography in Pyoderma Gangrenosum: A Pilot Study to Develop Criteria for Initial Diagnosis and Treatment Response — RECRUITING
• Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) — RECRUITING · PHASE2
• A MULTI-CENTRE, RANDOMISED, PLACEBO-CONTROLLED, DOUBLE BLIND, PARALLEL-GROUP TRIAL TO EVALUATE SAFETY AND EFFICACY OF SPESOLIMAB (BI 655130) IN ADULT PATIENTS WITH ULCERATIVE PYODERMA GANGRENOSUM (PG) WHO REQUIRE SYSTEMIC THERAPY — RECRUITING
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF GEVOKIZUMAB IN TREATING ACTIVE ULCERS OF PYODERMA GANGRENOSUM — RECRUITING
• A 2-YEAR, OPEN-LABEL, SAFETY EXTENSION STUDY OF GEVOKIZUMAB IN SUBJECTS WITH PYODERMA GANGRENOSUM — RECRUITING
• Study of treatments in Pyoderma Gangrenosum patients — COMPLETED · PHASE4
• A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy — TERMINATED · PHASE3
• Emerging Indications for Hyperbaric Oxygen Treatment — NOT_YET_RECRUITING · PHASE4
• Spesolimab in Pyoderma Gangrenosum — TERMINATED · PHASE2
• A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum — NOT_YET_RECRUITING · PHASE2
• A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum — NOT_YET_RECRUITING · PHASE2
• Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum — TERMINATED · PHASE3
• A Novel Therapeutic Treatment of Pyoderma Gangrenosum — TERMINATED · PHASE4
• Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum — WITHDRAWN · NA
• Hair follicle transplantation for hard to heal wounds: Non invasive asessment of skin regeneration — NOT_YET_RECRUITING
• A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG) — COMPLETED
• A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum — COMPLETED · PHASE2
• Deucravacitinib in PG — WITHDRAWN · PHASE1
• Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) — COMPLETED · PHASE2
• Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum — TERMINATED · PHASE3
• An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum — COMPLETED · PHASE2
• Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum — COMPLETED · PHASE2
• Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum — COMPLETED · PHASE1
• Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma — COMPLETED · PHASE1
• JAK-STAT Signaling Pathway in Pyoderma Gangrenosum — OTHER
• Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum — WITHDRAWN · PHASE2
• Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum — TERMINATED · PHASE2
• Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum — WITHDRAWN · PHASE2
• A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan — COMPLETED · PHASE3
• Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum — WITHDRAWN · PHASE2
• OPEN LABEL EXPLORATORY PHASE IIA TRIAL TO INVESTIGATE THE SAFETY AND EFFICACY OF IFX-1 IN TREATING SUBJECTS WITH PYODERMA GANGRENOSUM — COMPLETED · PHASE2
• Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum — OTHER
• Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease — COMPLETED · NA
• Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases — OTHER
• Canakinumab for Pyoderma Gangrenosum — COMPLETED · PHASE2
• A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum — TERMINATED · PHASE3
• An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum — TERMINATED · PHASE3
• An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum — TERMINATED · PHASE3
• Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum — COMPLETED · PHASE2

Refine this search